MET and cancer: The further identification of oncogenic mutations in human genes that coded for receptor tyrosine kinases acting as drivers in human cancers such as lung (EGFR), breast (HER2), gastric (c-Kit), renal and hepatocellular (MET) and thyroid (RET) cancers among others, illustrated the causative role of this family of proteins in cancer4,5.